Vaccine Development Studies

PPD has worked in vaccine development for more than 10 years offering full-service capabilities. In the past five years, we have conducted or supported 51 trials involving almost 1,200 sites and more than 36,000 patients.1 Our access to global populations, coupled with the ability to run large trials, minimizes the challenges associated with large-scale global research.

We have:

  • Unique expertise in hospital-based studies in early-phase vaccine development that includes new adjuvants and combination vaccines as well as later-stage field-based studies in targeted populations
  • Experience in monitoring a vast scope of protocols for vaccines, including bacterial and viral vaccine protocols for the National Institutes of Health (NIH) at vaccine treatment evaluation units across the United States
  • Standardized vaccine storage facilities, with back-to-base centralized alarm systems to protect the integrity of the serum
  • Expertise in coordinating the collection, storage and transportation of serum, including cold-chain monitoring

Unique Lab

Our comprehensive, centralized vaccines and biologics testing facility in Wayne, Pa., offers custom assay development, clinical testing and submission support services for new and modified vaccines as well as new uses of existing vaccines.

Biodefense Research

Since 2000, PPD has worked extensively with biodefense programs, including smallpox vaccine development. We have monitored numerous Category A biodefense protocols and are familiar with the complexities and unique challenges of this expanding therapeutic area.

Microbial Agent Experience

We have monitored trials for these infectious disease and vaccine indications:

  • Bacille Calmette-GuĂ©rin (BCG) vaccine for tuberculosis (TB)
  • Cholera
  • Diphtheria, tetanus, pertussis (DTP) vaccine
  • Escherichia coli
  • Haemophilus influenza B
  • Hepatitis B
  • Herpes simplex
  • HIV related
  • Influenza/parainfluenza
  • Malaria
  • Meningococcus
  • Mycobacterium vaccae
  • Parvovirus
  • Pertussis
  • Pneumococcus
  • Polio
  • Rabies
  • Rotavirus
  • Respiratory syncytial virus (RSV)
  • Salmonella typhi
  • Shigella sonnei
  • Staphylococcus aureus
  • Streptococcus
  • Group B streptococcus
  • S. gordonii
  • Yellow fever

1. These numbers don't include our work in the government sector, which is tracked separately.

PPD conducts a challenging children's vaccine trial successfully.
Read about findings related to tuberculosis risk factors.